179 related articles for article (PubMed ID: 10740143)
21. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
Arch Intern Med; 2001 Jan; 161(2):165-71. PubMed ID: 11176729
[TBL] [Abstract][Full Text] [Related]
22. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
Shah MR; Granger CB; Bart BA; McMurray JJ; Petrie MC; Michelson EL; Tudor GE; Swedberg K; Stevenson LW; Califf RM; Pfeffer MA
Am J Med; 2000 Oct; 109(6):489-92. PubMed ID: 11042239
[No Abstract] [Full Text] [Related]
23. Underutilisation of ACE inhibitors in patients with congestive heart failure.
Bungard TJ; McAlister FA; Johnson JA; Tsuyuki RT
Drugs; 2001; 61(14):2021-33. PubMed ID: 11735631
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.
Konstam MA
Eur Heart J; 1995 Dec; 16 Suppl N():59-64. PubMed ID: 8682063
[TBL] [Abstract][Full Text] [Related]
25. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
26. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals.
Philbin EF; Andreaou C; Rocco TA; Lynch LJ; Baker SL
Am J Cardiol; 1996 Apr; 77(10):832-8. PubMed ID: 8623735
[TBL] [Abstract][Full Text] [Related]
27. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
Gattis WA; Larsen RL; Hasselblad V; Bart BA; O'Connor CM
Am Heart J; 1998 Jul; 136(1):43-8. PubMed ID: 9665217
[TBL] [Abstract][Full Text] [Related]
28. Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.
Sigurdsson A; Swedberg K
Eur Heart J; 1995 Dec; 16 Suppl N():65-72. PubMed ID: 8682064
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
Thanikachalam S; Manchanda SC
Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
[TBL] [Abstract][Full Text] [Related]
30. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
31. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing.
Andersson F; Cline C; Rydén-Bergsten T; Erhardt L
Pharmacoeconomics; 1999 Jun; 15(6):535-50. PubMed ID: 10538327
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
34. Prescription of cardiovascular drugs in the French ODIN cohort of heart failure patients according to age and type of chronic heart failure.
Juillière Y; Suty-Selton C; Riant E; Darracq JP; Dellinger A; Labarre JP; Druelle J; Mulak G; Danchin N; Jourdain P;
Arch Cardiovasc Dis; 2014 Jan; 107(1):21-32. PubMed ID: 24388162
[TBL] [Abstract][Full Text] [Related]
35. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function.
Philbin EF; Rocco TA
Am Heart J; 1997 Aug; 134(2 Pt 1):188-95. PubMed ID: 9313596
[TBL] [Abstract][Full Text] [Related]
36. Improving practice patterns in heart failure through a national cardiological network: the case of ACE-inhibitors.
Porcu M; Opasich C; Scherillo M; Lucci D; De Maria R; Di Tano G; Maggioni AP;
Ital Heart J; 2002 Dec; 3(12):730-7. PubMed ID: 12611125
[TBL] [Abstract][Full Text] [Related]
37. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Nucl Med; 2003 Jun; 44(6):884-90. PubMed ID: 12791814
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study.
Grigorian Shamagian L; Roman AV; Ramos PM; Veloso PR; Bandin Dieguez MA; Gonzalez-Juanatey JR
J Card Fail; 2006 Mar; 12(2):128-33. PubMed ID: 16520261
[TBL] [Abstract][Full Text] [Related]
39. Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: a review of the literature.
Litaker JR; Chou JY
Clin Ther; 2003 Jul; 25(7):1918-35. PubMed ID: 12946542
[TBL] [Abstract][Full Text] [Related]
40. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
